Methylfolate (5-MTHF)
Last reviewed
Methylfolate (5-MTHF) is the bioactive form of folate that bypasses MTHFR genetic blocks. Since around 85% of hEDS patients carry an MTHFR variant, standard folic acid often won't convert efficiently. Methylfolate also regulates MMPs that degrade collagen and supports neurotransmitter synthesis. ZebraThrive uses 800 mcg daily in the AM stack.
At a Glance
Daily Dose
800 mcg daily (AM capsules)
Key Benefits
How It Works
Methylfolate bypasses the MTHFR enzyme block to provide active folate. It directly regulates MMP-2 promoter methylation to limit its hyperactivity (which otherwise leads to decorin cleavage and collagen weakness). It is also a mandatory cofactor for BH4 synthesis (essential for norepinephrine) and supports HNMT function to clear intracellular histamine.
What the Research Shows
Landmark study demonstrating exceptionally high prevalence of MTHFR variants in the hEDS population. Establishes the rationale for using the active form (L-methylfolate) rather than folic acid in this population.
Single-center prevalence study, Tulane EDS clinic
85% of hEDS patients carry MTHFR polymorphisms (double general population prevalence)
Mechanism + clinical case proposal
Low 5-MTHF levels correlate with MMP-2 hyperactivity and increased decorin cleavage in ligaments
L-5-methyltetrahydrofolate (L-5-MTHF) is the only folate species normally circulating in plasma. Pharmacokinetic comparisons show L-5-MTHF is at least as bioavailable as folic acid, and avoids the unmetabolized-folic-acid concerns that affect supplementation strategies in MTHFR-variant populations.
Authoritative PK + PD comparison review
L-5-MTHF at least as effective as folic acid for raising folate status and lowering plasma homocysteine; reduced risk of masking B12-deficiency hematological signs; reduced antifolate-drug interaction
16-week placebo-controlled RCT in 163 healthy adults
(6S)-5-MTHF produced equivalent or modestly better plasma + erythrocyte folate response than folic acid; supports use of 5-MTHF as the reference folate in intervention trials
Clinical case evidence for methylated B-vitamin support in COMT and MTHFR-variant POTS patients refractory to standard therapy.
BMJ Case Report, POTS patient refractory to conventional treatment
Patient with COMT Val158Met heterozygosity improved on methylated B vitamins after failing conventional POTS therapy; supports methylation as a clinical layer in autonomic phenotypes
Addressing the Triad
Tailored benefits for complex conditions
Methylfolate matters for MCAS through methylation-dependent histamine clearance. HNMT (histamine N-methyltransferase) is the primary intracellular histamine-degrading enzyme - it uses methyl groups from SAMe to inactivate histamine. SAMe regeneration depends on the methylfolate-B12 cycle running properly. Inadequate methylfolate is a real bottleneck for HNMT activity, and MTHFR polymorphisms (common in this community) make that bottleneck more likely. Methylfolate also supports the broader methylation pathway that affects multiple mediator clearance routes. The 800 mcg PM dose is conservative - therapeutic doses for depression run 15 mg, but MCAS patients can be sensitive to higher doses.
This is the hEDS evidence highlight of the formulation. A 2024 Tulane Fascia Institute study (Courseault et al.) found 85% of hEDS/HSD patients carry MTHFR polymorphisms - more than double the general population rate. The researchers proposed a 'folate-dependent hypermobility syndrome' model: when MTHFR is impaired, methylation suffers, and methylation directly affects MMP-2 gene regulation. MMP-2 derepression cleaves decorin and disrupts ECM organization - driving the hypermobility and tissue fragility patterns. Methylfolate bypasses the impaired enzyme. This is one of the rare ingredients with direct hEDS evidence at the population genetics level.
For POTS, methylfolate has two main pathways. First: BH4 (tetrahydrobiopterin) production. BH4 is the rate-limiting cofactor for synthesis of dopamine, norepinephrine, and serotonin - all directly relevant to autonomic regulation. Methylfolate is required for BH4 synthesis. Second: catecholamine clearance through COMT, a methylation-dependent enzyme. Slow methylation means catecholamines stay elevated longer than they should - directly relevant to hyperadrenergic POTS. A 2021 case report (Mittal) described hyperadrenergic POTS improvement with methylated B vitamins. The methylation stack (methylfolate + methylcobalamin + R5P) is foundational for autonomic balance in this community.
Why We Chose This Form
The most stable and bioavailable form of (6S)-5-MTHF. Bypasses metabolic blocks for 100% bioactivity. Superior stability to earlier calcium salts.
Form Comparison
(6S)-5-MTHF glucosamine salt
Stable salt form with ~50% first-pass absorption; the Quatrefolic-brand spec is one verified source, generic-OK
Folic Acid
Inactive synthetic form; requires MTHFR conversion (ineffective for 85% of hEDS)
Safety & Interactions
Potential Side Effects
Generally well-tolerated. Anxiety, irritability, or insomnia possible in sensitive overmethylators.
Drug Interactions
Antagonized by Methotrexate. May mask B12 deficiency (always paired with B12 in ZebraThrive).
Excipients to Avoid
- Artificial colors
- Corn-derived fillers
Safe Excipients
- HPMC capsules
- Rice flour
Always ensure B12 status is optimized alongside folate to prevent neurological masking.
How to Start
| Protocol Step | Suggested Dosage | Key Notes |
|---|---|---|
| Weeks 1-2 | 200 mcg daily | Assess methylation sensitivity |
| Weeks 3-4 | 400 mcg daily | Standard titration |
| Week 5+ | 800 mcg daily | Target maintenance |
"Neurotransmitter benefits within 2-4 weeks; ECM/collagen protection is a long-term mechanism."
State of the Evidence
While the genetic association is Grade A, clinical RCTs testing symptom reversal with methylfolate in hEDS are still pending.
- [1]MTHFR Polymorphisms in Patients With hEDSPMID: 38523329
Courseault J et al. (2024)
- [2]Folate-dependent hypermobility syndrome: A proposed mechanismPMID: 37095957
Courseault J et al. (2023)
- [3]Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamicsPMID: 20608755
Pietrzik K et al. (2010)
- [4]Comparison of (6S)-5-methyltetrahydrofolic acid v. folic acid as the reference folate in longer-term human dietary intervention studiesPMID: 19852872
Wright AJA et al. (2009)
- [5]Improvement of hyperadrenergic postural orthostatic tachycardia syndrome (POTS) with methylated B vitamins in the setting of a heterozygous COMT Val158Met polymorphismPMID: 34764114
Mittal N et al. (2021)
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .